NeuroOne Medical Technologies to Present at Key Neurology Conferences

NeuroOne Medical Technologies Corporation announced its participation in two significant medical industry conferences focused on neurological disorders and drug delivery systems. The medical technology company, which trades on Nasdaq under the symbol NMTC, will present at both the American Epilepsy Society 2025 Annual Meeting and the CNS Drug Delivery Summit in early December.

The company will first participate in the American Epilepsy Society Annual Meeting in Atlanta, Georgia from December 5th through December 9th. This conference serves as a gathering point for healthcare providers, scientists, advocates, industry professionals, and other experts dedicated to improving outcomes for epilepsy patients. Conference registration and information is available at https://www.aesnet.org/meetings_events/annual_meeting.

Following the epilepsy conference, NeuroOne will attend the CNS Drug Delivery Summit in Boston, Massachusetts from December 9th through December 11th. This seventh annual summit brings together more than 100 industry experts including neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, and delivery specialists. The event focuses on collaborative efforts to develop cutting-edge strategies for overcoming the unique challenges associated with delivering drugs to the brain. Additional conference details can be found at https://www.cnsdrugdelivery.com.

NeuroOne's participation in these conferences underscores the growing importance of advanced medical technologies in treating neurological conditions. The company's focus on developing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation addresses critical needs in neurological care. These technologies have potential applications for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries.

The significance of NeuroOne's conference participation extends beyond corporate visibility. As neurological disorders affect millions worldwide, advancements in treatment technologies could substantially improve patient outcomes while potentially reducing healthcare costs. The company's work in drug delivery systems specifically addresses one of the most challenging aspects of neurological treatment - effectively delivering medications across the blood-brain barrier.

Industry conferences like those NeuroOne will attend serve as crucial platforms for sharing research findings, fostering collaborations, and accelerating the development of new treatments. The company's presence at both events indicates its commitment to engaging with the broader medical community and contributing to the advancement of neurological care. For investors and healthcare professionals, NeuroOne's active participation in these forums signals ongoing progress in their technology development and potential future applications in the rapidly evolving field of neurological treatment.